摘要
目的探讨同时性多发性垂体神经内分泌肿瘤/腺瘤(multiple synchronous PitNET/adenomas of distinct lineages,MSPs)的不同谱系肿瘤细胞组成部分,并进行准确的组织学分型为确定手术后的随访计划和辅助治疗提供重要依据。方法收集855例垂体神经内分泌肿瘤临床资料,按照新版WHO标准重新分类,对13例被明确诊断为MSPs的临床病理特征进行回顾性分析,运用免疫组化EnVision两步法分析PIT-1、SF-1、T-PIT、GH、PRL、TSH、LH、FSH、ACTH等表达,并复习相关文献。结果(1)患者年龄39~68岁,中位年龄55岁,女性患者7例;男性患者6例;(2)影像学表现:肿瘤最大径1.2~3.8 cm(平均2.5 cm)。13例均为大腺瘤,影像学均无法评估MSPs与单一谱系垂体神经内分泌肿瘤(pituitary neuroendocrine tumors,PitNETs);(3)临床表现:3例出现高泌乳素血症,均包含分泌PRL的PitNETs成分,1例为未成熟PIT-1多激素细胞瘤、1例为致密颗粒型泌乳素细胞瘤及1例嗜酸性干细胞瘤。1例患者为库欣病,包含Crooke细胞瘤成分;2例检测到ACTH升高,其中1例包含促肾上腺皮质细胞瘤成分。在无激素过量证据的2例患者中,均含有促性腺激素细胞瘤成分;(4)组合形式:两种细胞谱系组合11例(SF-1谱系与PIT-1谱系组合5例;T-PIT谱系与PIT-1谱系组合4例;零细胞瘤与PIT-1谱系1例;未明确谱系多激素细胞瘤与SF-1谱系1例);三种细胞组合2例(零细胞瘤、PIT-1谱系与T-PIT谱系);其中13例病例均为PIT-1谱系肿瘤,46.2%(6/13)为促性腺激素细胞瘤,38.5%(5/13)为泌乳素细胞瘤;(5)10例患者组合中存在高风险谱系肿瘤:3例未成熟PIT-1多激素PitNETs、1例Crooke细胞PitNETs、1例嗜酸性干细胞PitNETs、3例零细胞PitNETs及4例静默型稀疏颗粒型促肾上腺皮质激素PitNETs;其中2例为两种高风险亚型肿瘤组合。结论本中心MSPs均为大腺瘤,其发生率虽仅为PitNETs的1.5%,但2/3病例存在高风险谱系肿瘤成分,垂体细胞谱系转录因子与腺垂体激素的使用对于区分和明确MSPs不同成分具有重要作用。
Purpose To investigate the cell components in different tumor lineages of multiple synchronous pituitary neuroendocrine tumors(PitNETs)/neuroendocrine tumors(MSPs)and to carry out accurate histological typing,which provides an important basis for determining the follow-up plan and adjuvant therapy after surgery.Methods The clinical data of 855 patients with PitNETs were collected and reclassified according to the new WHO standard.The clinicopathological features of 13 patients diagnosed as MSPs were analyzed retrospectively.The immunohistochemical EnVision two-step method was used to detect the expression of PIT-1,SF-1,T-PIT,GH,PRL,TSH,LH,FSH,ACTH,etc.,and related literatures were reviewed.Methods A total of 855 cases of pituitary neuroendocrine tumor from the second hospital of the Chinese Hebei Medical University were collected and reclassified according to the new WHO standard,and review the literature.Results(1)The age of patients were 39-68 years with median age of 55 years.7 cases were female and 6 were male;(2)Imaging findings:There was 1.2~3.8 cm(mean 2.5 cm)in maximum tumor diameter.13 patients were large adenomas,neither MSPs nor single lineage PitNETs could not assessed on imaging;(3)Clinical manifestations:3 cases had hyperprolactinemia which all containing PitNETs components of PRL,one case was immature PIT-1 polyhormone cell tumor,one was dense granular prolactinoma,and one case was eosinophilic stem tumor.One patient had Cushing’s disease and contained a Crook cell tumor component;two had elevated ACTH,and one had an adrenocorticotropic adenomatous component.In the two patients with no evidence of hormone excess,all contained gonadotropin cell tumor components;(4)Combination form:11 cases of the combination of the two cell lineages(5 cases of combination of SF-1 lineage and PIT-1 lineage;4 cases of combination of T-PIT lineage and PIT-1 lineage;1 case of null cell tumor and PIT-1 lineage;1 case of plurihormonal PitNETs and SF-1 lineage);Two cases of three cell combinations(null cell tumor,PIT-1 lineage,and T-PIT lineage);Among them,13 cases were PIT-1 lineage tumors,46.2%(6/13)were gonadotropin cell tumor,38.5%(5/13)were prolactinoma;(5)The presence of high-risk lineage tumors in the 10 patient combinations:3 immature PIT-1-lineage tumor,1 Crooke cell PitNETs,1 acidophil stem cells tumor,3 zero-cell PitNETs,and 4 silent-type sparse granular adrenocorticotropic hormone PitNETs;Two of them were combinations of two high-risk subtypes.Conclusion MSPs in our center are large adenomas,although their incidence is only 1.5%of PitNETs,2/3 cases have high-risk lineage tumor components,and the use of pituitary cell lineage transcription factors and adenohypophyseal hormones plays an important role in distinguishing and clarifying the different components of MSPs.
作者
杜世璇
付雨桐
邵琪琪
郭文丽
郝增方
娄蕾
李月红
DU Shixuan;FU Yutong;SHAO Qiqi;GUO Wenli;HAO Zengfang;LOU Lei;LI Yuehong(Department of Pathology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)
出处
《临床与实验病理学杂志》
CAS
北大核心
2024年第5期490-496,共7页
Chinese Journal of Clinical and Experimental Pathology
基金
河北省政府资助临床医学优秀人才项目(ZF2024036)
河北省中央引导地方科技发展资金项目(236Z7747G)
河北省医学适用技术跟踪项目(GZ2021045)。
